Expanding targeted therapies for NSCLC

    Cancer Discovery
    |December 6, 2014
    PubMed

    Insights

    Dabrafenib shows promise for BRAF-mutant non-small cell lung cancer. However, preliminary data for neratinib in HER2-mutant lung cancer are inconclusive regarding patient benefit.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Non-small cell lung cancer (NSCLC) harbors diverse molecular alterations.
    • Targeted therapies offer new treatment avenues for specific NSCLC subtypes.

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.2K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    1.8K
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    6.4K
    Modified-Release Drug Delivery Systems: Site-Targeted01:24

    Modified-Release Drug Delivery Systems: Site-Targeted

    Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
    144